IMR-687

DRUG8 trials

Sponsors

IMARA, Inc., Cardurion Pharmaceuticals, Inc., Imara, Inc.

Conditions

Heart Failure With Preserved Ejection FractionReduced Hb in red blood cells (RBCs), decreased RBC production, and anemia due to reduced or absent synthesis of the ß chain of hemoglobin (Hb) and mutations in the hemoglobin beta (HBB) gene in subjects with ß-thalassemia. ThalassemiaSickle Beta 0 ThalassemiaSickle Cell DiseaseSickle-Cell; Hb-SCThe population for this study includes subjects with the following forms of SCD: homozygous sickle hemoglobin (HbSS), sickle-ß° (HbSB°) thalassemia, and sickle-ß? (HbSB?) thalassemia. Sickle cellβ Thalassemia

Phase 1

A Study of IMR-687 in Healthy Adult Volunteers

CompletedNCT02998450

Cardurion Pharmaceuticals, Inc.Sickle Beta 0 Thalassemia, Sickle Cell Disease, Sickle-Cell; Hb-SC

Start: 2016-10-18End: 2017-07-08Updated: 2025-05-15

Phase 2

A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)

CompletedNCT03401112

Cardurion Pharmaceuticals, Inc.Sickle Cell Disease

Start: 2018-01-26End: 2020-08-28Updated: 2025-05-15

An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia

Active, not recruitingNCT04053803

Imara, Inc.Sickle Cell Disease

Start: 2019-05-22End: 2025-03-31Target: 30Updated: 2022-03-04

A Study of IMR-687 in Subjects With Beta Thalassemia

TerminatedNCT04411082

Cardurion Pharmaceuticals, Inc.β Thalassemia

Start: 2020-10-16End: 2022-05-04Updated: 2025-05-15

A Study of IMR-687 in Subjects With Sickle Cell Disease

TerminatedNCT04474314

Cardurion Pharmaceuticals, Inc.Sickle Cell Disease

Start: 2020-08-13End: 2022-05-04Updated: 2025-05-15

A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease

Active, not recruitingLBCTR2020083421

IMARA, Inc.The population for this study includes subjects with the following forms of SCD: homozygous sickle hemoglobin (HbSS), sickle-ß° (HbSB°) thalassemia, and sickle-ß? (HbSB?) thalassemia. Sickle cell

Start: 2020-11-02Target: 99Updated: 2026-02-02

A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia

Active, not recruitingLBCTR2020093402

IMARA, Inc.Reduced Hb in red blood cells (RBCs), decreased RBC production, and anemia due to reduced or absent synthesis of the ß chain of hemoglobin (Hb) and mutations in the hemoglobin beta (HBB) gene in subjects with ß-thalassemia. Thalassemia

Start: 2020-10-01Target: 120Updated: 2026-02-02

Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction

WithdrawnNCT05312021

Cardurion Pharmaceuticals, Inc.Heart Failure With Preserved Ejection Fraction

Start: 2022-04-30End: 2023-11-30Updated: 2025-05-15

Related Papers

Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

Blood2021-11-056 citations

PDE9 Inhibition By IMR-687 Improves Markers of Beta-Thalassemia in the Hbb th1/th1 Experimental Mouse Model

Blood2021-11-05